Caladrius Biosciences (NASDAQ:CLBS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.20, Fidelity Earnings reports.
Shares of CLBS traded down $0.68 during midday trading on Friday, hitting $4.53. 21,628 shares of the company traded hands, compared to its average volume of 36,147. Caladrius Biosciences has a one year low of $2.91 and a one year high of $11.65. The stock has a market cap of $47.56 million, a PE ratio of -2.54 and a beta of 1.22.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research report on Wednesday, September 12th. HC Wainwright upped their price target on Caladrius Biosciences to $15.00 and gave the company a “buy” rating in a research report on Monday, September 10th. Finally, Chardan Capital reiterated a “buy” rating on shares of Caladrius Biosciences in a research report on Wednesday, August 29th.
About Caladrius Biosciences
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Featured Story: Fundamental Analysis
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.